On July 2, Hansoh Pharmaceutical rose 6.01% in regular trading, trading at 31.44 HKD/share, with turnover of approximately 205 million HKD.

On the news front, the company announced on June 30 that its innovative drug pemosatide injection received a drug registration certificate, marking the first domestically developed long-acting ESA product to gain approval in China, signaling accelerated commercialization of its innovation pipeline. Concurrently, the broader pharmaceutical sector rallied strongly, with United Lab up 8.78%, Simcere Pharma up 8.02%, and CSPC Pharma up 7.17%.

Catalysts have been released in rapid succession for the company. Its weight-loss drug olatorepatide injection and HS-10568 injection NDA submissions were both accepted by China NMPA in June. Additionally, a 10% share buyback authorization was passed at the annual general meeting on June 26. Multiple institutions maintain Buy ratings with target prices ranging from 40 to 46.41 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)